Xiang enterprise science and technology board ushered in the pharmaceutical enterprises! Nanxin Pharmaceuticals Shows Great Innovation Capability

Pharmaceutical Network Enterprise News: Hunan Liuyang enterprise listing work ushered in the opening of the red, Xiang enterprise science and technology board ushered in pharmaceutical enterprisesHunan Nanxin Pharmaceutical Co., Ltd., located in the area of Liuyang, is listed on the Shanghai Stock Exchange and officially landed on the Science and Technology Board, with stock code 688189, which is also the 8th listed enterprise in Liuyang
Founded in 2006, Nanxin Pharmaceuticals is an innovative pharmaceutical company focused on the research and development, production and marketing of chemical drugs, committed to major diseases, sudden diseases of new drugs and special effects drug research and development and industrialization, mastered anti-infection, cardiovascular, anti-tumor and other drugs a number of core technologies
Nanxin Pharmaceuticals issued 35 million shares in the public, the issue price of 34.94 yuan, a total of 122,29 million yuan raised, mainly used for innovative drug research and development projects, marketing channelnetwork network upgrade construction projects and supplementary liquidityNanxin Pharmaceuticalsuccessfully broke through the science and technology board, not only fully to the market to understand the excellent market performance of enterprises, excellent scientific and technological innovation capabilities, but also to expand the liuyang listed enterprise team
Data show that from 2017 to 2019, Nanxin Pharmaceuticals achieved operating income of RMB348 million, RMB701 million and RMB1,014 million, respectively, and achieved net profit of RMB 0.27 billion, RMB 554 million and RMB91 million, respectively, and the net profit of revenue and mother-to-mother maintained high growth
At present, the company has been listed as the main product for the innovative drug ParamiveAccording to the prospectus, the innovative drug Paramive achieved sales revenue of 520 million yuan in 2019, a significant increase of 242.20% YoYIt is understood that Paramive was approved for listing in April 2013, is the National Health and Planning Commission issued the "influenza diagnosis and treatment program (2019 version)" one of the main recommended drugs, in recent years because of clinical efficacy has been recognized to achieve rapid release
In addition to the listed Paramive, Nanxin Pharmaceuticals currently has three class 1 innovative drugs and two improved new drugs in the research, which will support the company's future performance growthAmong them, the anti-tumor drug metafenni is in phase I clinical trial stage, diabetic nephrotic kidney disease treatment drug mefloquinone has been approved clinically, the remaining 3 anti-flu drugs in the preclinical research stage
The pharmaceutical industry is an industry that needs to innovate, and if research and development and innovation are not sustained, it is likely to lag behind or even be eliminatedOnly the innovation, only the innovation strong, in the country to strengthen the support capacity of science and technology, encourage research and development innovation, the accumulation of professional personnel increasingly rich premise, the soil of domestic pharmaceutical enterprises innovation is increasingly fertileAs a leader in innovative pharmaceutical enterprises, Nanxin Pharmaceuticals has responded positively to the relevant strategic planning of the national pharmaceutical industry since its inception, and is committed to the research and development and industrialization of new and special drugs for major diseases and sudden diseases in order to better meet the demand for clinical drugs
It is understood that with the above-mentioned research and products on sale matching, Nanxin Pharmaceuticals in recent years has been increasing investment in research and development, and the company raised more than 60% of the funds for research and developmentAccording to the prospectus, from 2017 to 2019, the company's research and development investment was RMB22.068 million, RMB45.2577 million and RMB71.7649 million, respectively, of which the growth rate of research and development investment in 2018 and 2019 was as high as 105.08 percent and 58.57 percent, respectively
New drug research and development cycle is long, high risk, for this, Nanxin Pharmaceuticals adhere to the "independent research and development and commissioned research" combined with the research and development model, to "cooperative research and development" as a supplementary means of research and development projects, committed to new product research and development, to ensure the existing and increasing innovation research and development projects steadily In the future, Nanxin Pharmaceuticals will steadily promote the market expansion of existing products, while focusing on research and development innovation work, increasing research and development investment, enrich existing varieties and reserve expansion product lines, to inject new vitality into the company's development, to ensure sustainable growth in the company's performance.